{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:45:20Z","timestamp":1791420320210,"version":"4.3.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medilink Midlands and the East Midlands Academic Health Science Network : Grant : MTT-ISG-INS-161"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate clinical outcomes and resource utilisation of conventional treatment modalities for ocular surface disease involving inflammation and persistent epithelial defect (PED) in an NHS setting, and to compare outcomes with sutureless human amniotic membrane-derived dry matrix (HAMDM) as an alternative therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective clinical study of 30 patients with PED was conducted across two centres. Treatment duration, healing rates, outpatient (OP) burden, and associated costs were analysed. Outcomes were benchmarked against pooled data from prior studies with HAMDM at the same centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Conventional management achieved complete healing in 57% of patients, with a mean treatment duration of 176\u2009\u00b1\u2009188 days and 10 OP visits per case. Adjunctive procedures such as tarsorrhaphy (83%) and amniotic membrane transplantation (AMT, 34%) were frequently required. The average total cost per patient was \u00a3 4900\u2009\u00b1\u2009\u00a3 3363. In comparison, patients treated with HAMDM achieved higher resolution rates (63%), shorter treatment duration (98 days), fewer OP appointments (8 per case), and a lower treatment cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PED poses a substantial clinical and economic burden within the NHS. Standard treatments are prolonged and resource-intensive. HAMDM represents a clinically effective and cost-saving alternative, potentially reducing treatment duration, OP burden and overall healthcare costs. Hospital Episode Statistics (HES) data revealed over 138,000 PED-related episodes annually in the NHS, primarily managed in non-surgical settings. These findings therefore support further integration of sutureless amniotic membrane into first-line care strategies for ocular surface disease involving inflammation and PED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04314-6","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:07:12Z","timestamp":1780556832000},"page":"1627-1636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS)"],"prefix":"10.1038","volume":"40","author":[{"given":"Sundas Ejaz","family":"Maqsood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John William","family":"Posnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elalfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"4314_CR1","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/OPTH.S299141","volume":"15","author":"S Maqsood","year":"2021","unstructured":"Maqsood S, Elsawah K, Dhillon N, Soliman S, Laginaf M, Lodhia V, et al. Management of persistent corneal epithelial defects with human amniotic membrane-derived dry matrix. Clin Ophthalmol. 2021;15:2231\u20138.","journal-title":"Clin Ophthalmol"},{"key":"4314_CR2","first-page":"163","volume":"8","author":"U Vaidyanathan","year":"2019","unstructured":"Vaidyanathan U, Hopping GC, Liu HY, Somani AN, Ronquillo YC, Hoopes PC, et al. Persistent corneal epithelial defects: a review article. Med Hypothesis Discov Innov Ophthalmol. 2019;8:163\u201376.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"4314_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3928\/1081597X-20171128-01","volume":"34","author":"SE Wilson","year":"2018","unstructured":"Wilson SE, Medeiros CS, Santhiago MR. Pathophysiology of corneal scarring in persistent epithelial defects after PRK and other corneal injuries. J Refract Surg. 2018;34:59\u201364.","journal-title":"J Refract Surg"},{"key":"4314_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.sjopt.2014.06.011","volume":"28","author":"LR Katzman","year":"2014","unstructured":"Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol. 2014;28:168\u201372.","journal-title":"Saudi J Ophthalmol"},{"key":"4314_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/ICO.0000000000002179","volume":"39","author":"K Schuerch","year":"2020","unstructured":"Schuerch K, Baeriswyl A, Frueh BE, Tappeiner C. Efficacy of amniotic membrane transplantation for the treatment of corneal ulcers. Cornea. 2020;39:479\u201383.","journal-title":"Cornea"},{"key":"4314_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jtos.2014.12.005","volume":"13","author":"B Wirostko","year":"2015","unstructured":"Wirostko B, Rafii M, Sullivan DA, Morelli J, Ding J. Novel therapy to treat corneal epithelial defects: a hypothesis with growth hormone. Ocul Surf. 2015;13:204\u201312.e1.","journal-title":"Ocul Surf"},{"key":"4314_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ajo.2020.05.035","volume":"218","author":"S Sinha","year":"2020","unstructured":"Sinha S, Singh RB, Dohlman TH, Wang M, Taketani Y, Yin J, et al. Prevalence of persistent corneal epithelial defects in chronic ocular graft-versus-host disease. Am J Ophthalmol. 2020;218:296\u2013303.","journal-title":"Am J Ophthalmol"},{"key":"4314_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.survophthal.2023.06.001","volume":"68","author":"ZZ Thia","year":"2023","unstructured":"Thia ZZ, Ho YT, Shih KC, Tong L. New developments in the management of persistent corneal epithelial defects. Surv Ophthalmol. 2023;68:1093\u2013114.","journal-title":"Surv Ophthalmol"},{"key":"4314_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.exer.2005.09.021","volume":"82","author":"MV Netto","year":"2006","unstructured":"Netto MV, Mohan RR, Sinha S, Sharma A, Dupps W, Wilson SE. Stromal haze, myofibroblasts, and surface irregularity after PRK. Exp Eye Res. 2006;82:788\u201397.","journal-title":"Exp Eye Res"},{"key":"4314_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/ICL.0000000000000261","volume":"43","author":"WY Wang","year":"2017","unstructured":"Wang WY, Lee YK, Tsai SH, Lin YC, Chen YM. Autologous serum eye drops combined with silicone hydrogen lenses for the treatment of postinfectious corneal persistent epithelial defects. Eye Contact Lens. 2017;43:225\u20139.","journal-title":"Eye Contact Lens"},{"key":"4314_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00417-006-0257-y","volume":"244","author":"S Schrader","year":"2006","unstructured":"Schrader S, Wedel T, Moll R, Geerling G. Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects. Graefes Arch Clin Exp Ophthalmol. 2006;244:1345\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4314_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/ICL.0b013e318233c9bb","volume":"37","author":"JA Choi","year":"2011","unstructured":"Choi JA, Chung SH. Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects. Eye Contact Lens. 2011;37:370\u20133.","journal-title":"Eye Contact Lens"},{"key":"4314_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/ICO.0000000000003204","volume":"42","author":"V Romano","year":"2023","unstructured":"Romano V, Bignotti S, Forbice E, Bianchetti A, Almici C, Semeraro F. Allogeneic solid platelet-rich plasma for persistent epithelial neurotrophic defects: a protocol and pilot study. Cornea. 2023;42:498\u2013506.","journal-title":"Cornea"},{"key":"4314_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.transci.2014.12.027","volume":"52","author":"C Ronci","year":"2015","unstructured":"Ronci C, Ferraro AS, Lanti A, Missiroli F, Sinopoli S, Del Proposto G, et al. Platelet-rich plasma as treatment for persistent ocular epithelial defects. Transfus Apher Sci. 2015;52:300\u20134.","journal-title":"Transfus Apher Sci"},{"key":"4314_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10384-012-0175-y","volume":"56","author":"KM Kim","year":"2012","unstructured":"Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol. 2012;56:544\u201350.","journal-title":"Jpn J Ophthalmol"},{"key":"4314_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/sctm.18-0140","volume":"8","author":"JDM Campbell","year":"2019","unstructured":"Campbell JDM, Ahmad S, Agrawal A, Bienek C, Atkinson A, Mcgowan NWA, et al. Allogeneic ex vivo expanded corneal epithelial stem cell transplantation: a randomized controlled clinical trial. Stem Cells Transl Med. 2019;8:323\u201331.","journal-title":"Stem Cells Transl Med"},{"key":"4314_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/bjophthalmol-2020-318496","volume":"107","author":"D Harminder Singh","year":"2023","unstructured":"Harminder Singh D, Darren Shu Jeng T, Ahmed A, Dalia GS. Management of limbal stem cell deficiency by amnion-assisted conjunctival epithelial redirection using vacuum-dried amniotic membrane and fibrin glue. Br J Ophthalmol. 2023;107:342.","journal-title":"Br J Ophthalmol"},{"key":"4314_CR18","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41433-020-01333-9","volume":"35","author":"G Moussa","year":"2021","unstructured":"Moussa G, Hodson J, Gooch N, Virdee J, Penaloza C, Kigozi J, et al. Calculating the economic burden of presumed microbial keratitis admissions at a tertiary referral centre in the UK. Eye. 2021;35:2146\u201354.","journal-title":"Eye"},{"key":"4314_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41433-020-01360-6","volume":"35","author":"P Hossain","year":"2021","unstructured":"Hossain P. Microbial keratitis\u2014the true costs of a silent pandemic? Eye. 2021;35:2071\u20132.","journal-title":"Eye"},{"key":"4314_CR20","first-page":"367","volume":"91","author":"JP McCulley","year":"1993","unstructured":"McCulley JP, Horowitz B, Husseini ZM, Horowitz M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group. Trans Am Ophthalmol Soc. 1993;91:367\u201386.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"4314_CR21","doi-asserted-by":"crossref","unstructured":"Goodman C, Davies SL, Gordon AL, Dening T, Gage H, Meyer J, et al. Optimal NHS service delivery to care homes: a realist evaluation of the features and mechanisms that support effective working for the continuing care of older people in residential settings. Southampton (UK); NIHR Journals Library: 2017.","DOI":"10.3310\/hsdr05290"},{"key":"4314_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2147\/OPTH.S456864","volume":"18","author":"S Maqsood","year":"2024","unstructured":"Maqsood S, Elalfy M. Management of ocular surface inflammation with persistent epithelial defects using a sutureless human amniotic membrane dehydrated matrix: a prospective study utilizing a digital ocular surface assessment tool. Clin Ophthalmol. 2024;18:1467\u201378.","journal-title":"Clin Ophthalmol"},{"key":"4314_CR23","unstructured":"Golhait. P PR. Persistent epithelial defect. StatPearls: Treasure Island (FL): StatPearls publishing; 2023 [updated 2023 Jul 31. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK573060\/."},{"key":"4314_CR24","doi-asserted-by":"crossref","unstructured":"Koay SY, Larkin DFP. New pharmacological approaches for the treatment of neurotrophic keratitis. Front Pharmacol. 2022;13:796854.","DOI":"10.3389\/fphar.2022.796854"},{"key":"4314_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jtos.2021.02.006","volume":"20","author":"AA Ahmmed","year":"2021","unstructured":"Ahmmed AA, Ting DSJ, Figueiredo FC. Epidemiology, economic and humanistic burdens of ocular surface chemical injury: a narrative review. Ocul Surf. 2021;20:199\u2013211.","journal-title":"Ocul Surf"},{"key":"4314_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40123-021-00349-y","volume":"10","author":"C Cartes","year":"2021","unstructured":"Cartes C, Lako M, Figueiredo FC. Referral patterns of patients with limbal stem cell deficiency to a specialized tertiary center in the United Kingdom. Ophthalmol Ther. 2021;10:535\u201345.","journal-title":"Ophthalmol Ther"},{"key":"4314_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/jcp.25623","volume":"232","author":"L Mastropasqua","year":"2017","unstructured":"Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M. Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. J Cell Physiol. 2017;232:717\u201324.","journal-title":"J Cell Physiol"},{"key":"4314_CR28","first-page":"228424031877715","volume":"2018","author":"S Stanisic","year":"2018","unstructured":"Stanisic S, Marocco A, Gallo A, Rama P, Sacchetti M, Rolando M, et al. Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy. Glob Reg Health Technol Assess. 2018;2018:2284240318777150.","journal-title":"Glob Reg Health Technol Assess"},{"key":"4314_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.survophthal.2018.12.003","volume":"64","author":"L Ung","year":"2019","unstructured":"Ung L, Bispo PJM, Shanbhag SS, Gilmore MS, Chodosh J. The persistent dilemma of microbial keratitis: global burden, diagnosis, and antimicrobial resistance. Surv Ophthalmol. 2019;64:255\u201371.","journal-title":"Surv Ophthalmol"},{"key":"4314_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/bjophthalmol-2020-316128","volume":"105","author":"T Darren Shu Jeng","year":"2021","unstructured":"Darren Shu Jeng T, Charlotte Shan H, Jessica C, Ahmad E, Mouhamed A-A, Tim B, et al. 12-year analysis of incidence, microbiological profiles and in vitro antimicrobial susceptibility of infectious keratitis: the Nottingham Infectious Keratitis Study. Br J Ophthalmol. 2021;105:328.","journal-title":"Br J Ophthalmol"},{"key":"4314_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.18240\/ijo.2022.01.13","volume":"15","author":"K Sarici","year":"2022","unstructured":"Sarici K, Petkovsek D, Martin A, Yuan A, Goshe JM, Srivastava SK, et al. Corneal epithelial defects following vitreoretinal surgery: incidence and outcomes from the DISCOVER study. Int J Ophthalmol. 2022;15:83\u20138.","journal-title":"Int J Ophthalmol"},{"key":"4314_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/ojo.OJO_122_2016","volume":"10","author":"AS Al-Hinai","year":"2017","unstructured":"Al-Hinai AS. Corneal epithelial defect after pars plana vitrectomy. Oman J Ophthalmol. 2017;10:162\u20136.","journal-title":"Oman J Ophthalmol"},{"key":"4314_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2119\/molmed.2010.00046","volume":"16","author":"JH Rhim","year":"2010","unstructured":"Rhim JH, Kim JH, Yeo E-J, Kim JC, Park SC. Caveolin-1 as a novel indicator of wound-healing capacity in aged human corneal epithelium. Mol Med. 2010;16:527\u201334.","journal-title":"Mol Med"},{"key":"4314_CR34","first-page":"700","volume":"25","author":"L Chou","year":"1994","unstructured":"Chou L, Cohen EJ, Laibson PR, Rapuano CJ. Factors associated with epithelial defects after penetrating keratoplasty. Ophthalmic Surg. 1994;25:700\u20133.","journal-title":"Ophthalmic Surg"},{"key":"4314_CR35","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.18240\/ijo.2019.12.17","volume":"12","author":"H Zhao","year":"2019","unstructured":"Zhao H, He Y, Ren YR, Chen BH. Corneal alteration and pathogenesis in diabetes mellitus. Int J Ophthalmol. 2019;12:1939\u201350.","journal-title":"Int J Ophthalmol"},{"key":"4314_CR36","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00417-008-0797-4","volume":"246","author":"S Rumelt","year":"2008","unstructured":"Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U. Persistent epithelial defects and ulcers in repeated corneal transplantation: incidence, causative agents, predisposing factors and treatment outcomes. Graefes Arch Clin Exp Ophthalmol. 2008;246:1139\u201345.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4314_CR37","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9:e489\u2013e551.","journal-title":"Lancet Glob Health"},{"key":"4314_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.addr.2018.01.006","volume":"126","author":"M Ziaei","year":"2018","unstructured":"Ziaei M, Greene C, Green CR. Wound healing in the eye: therapeutic prospects. Adv Drug Deliv Rev. 2018;126:162\u201376.","journal-title":"Adv Drug Deliv Rev"},{"key":"4314_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00003226-200011000-00001","volume":"19","author":"JJ Reidy","year":"2000","unstructured":"Reidy JJ, Paulus MP, Gona S. Recurrent erosions of the cornea: epidemiology and treatment. Cornea. 2000;19:767\u201371.","journal-title":"Cornea"},{"key":"4314_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clae.2003.09.004","volume":"27","author":"R Arora","year":"2004","unstructured":"Arora R, Jain S, Monga S, Narayanan R, Raina UK, Mehta DK. Efficacy of continuous wear PureVision contact lenses for therapeutic use. Cont Lens Anterior Eye. 2004;27:39\u201343.","journal-title":"Cont Lens Anterior Eye"},{"key":"4314_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/archopht.1973.01000050369006","volume":"90","author":"CH Dohlman","year":"1973","unstructured":"Dohlman CH, Boruchoff SA, Mobilia EF. Complications in use of soft contact lenses in corneal disease. Arch Ophthalmol. 1973;90:367\u201371.","journal-title":"Arch Ophthalmol"},{"key":"4314_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/archopht.1974.03900060285007","volume":"91","author":"SI Brown","year":"1974","unstructured":"Brown SI, Bloomfield S, Pearce DB, Tragakis M. Infections with the therapeutic soft lens. Arch Ophthalmol. 1974;91:275\u20137.","journal-title":"Arch Ophthalmol"},{"key":"4314_CR43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/ICL.0b013e31829fadde","volume":"39","author":"A Saini","year":"2013","unstructured":"Saini A, Rapuano CJ, Laibson PR, Cohen EJ, Hammersmith KM. Episodes of microbial keratitis with therapeutic silicone hydrogel bandage soft contact lenses. Eye Contact Lens. 2013;39:324\u20138.","journal-title":"Eye Contact Lens"},{"key":"4314_CR44","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1177\/11206721211048372","volume":"32","author":"S \u00d6zbek-Uzman","year":"2022","unstructured":"\u00d6zbek-Uzman S, Yaln\u0131z-Akkaya Z, \u015eingar \u00d6zdemir E, Burcu A. Treatment of persistent epithelial defects with single-dose autologous serum eye drops. Eur J Ophthalmol. 2022;32:2159\u201365.","journal-title":"Eur J Ophthalmol"},{"key":"4314_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.clae.2016.06.003","volume":"39","author":"YK Lee","year":"2016","unstructured":"Lee YK, Lin YC, Tsai SH, Chen WL, Chen YM. Therapeutic outcomes of combined topical autologous serum eye drops with silicone-hydrogel soft contact lenses in the treatment of corneal persistent epithelial defects: a preliminary study. Cont Lens Anterior Eye. 2016;39:425\u201330.","journal-title":"Cont Lens Anterior Eye"},{"key":"4314_CR46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jfo.2022.07.001","volume":"46","author":"H Zhang","year":"2023","unstructured":"Zhang H, Li Y, Chen G, Han F, Jiang W. Human amniotic membrane graft for refractory macular hole: a single-arm meta-analysis and systematic review. J Fr Ophtalmol. 2023;46:276\u201386.","journal-title":"J Fr Ophtalmol"},{"key":"4314_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6600788","volume":"2022","author":"YM Chen","year":"2022","unstructured":"Chen YM, Wang WY, Lin YC, Tsai SH, Lou YT. Use of autologous serum eye drops with contact lenses in the treatment of chemical burn-induced bilateral corneal persistent epithelial defects. Biomed Res Int. 2022;2022:6600788.","journal-title":"Biomed Res Int"},{"key":"4314_CR48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/vox.12502","volume":"112","author":"DC Marks","year":"2017","unstructured":"Marks DC, van der Meer PF. Serum eye drops: a survey of international production methods. Vox Sang. 2017;112:310\u20137.","journal-title":"Vox Sang"},{"key":"4314_CR49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/bjophthalmol-2015-306842","volume":"100","author":"NG Soni","year":"2016","unstructured":"Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100:22\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4314_CR50","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1442-9071.2012.02795.x","volume":"40","author":"S Holland","year":"2012","unstructured":"Holland S, Morck D, Schultz C. Treatment of corneal defects with delayed re-epithelization with a medical device\/drug delivery system for epidermal growth factor. Clin Exp Ophthalmol. 2012;40:662\u20138.","journal-title":"Clin Exp Ophthalmol"},{"key":"4314_CR51","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/bjo.81.5.391","volume":"81","author":"MMMJ Dellaert","year":"1997","unstructured":"Dellaert MMMJ, Casey TA, Wiffen S, Gordon J, Johnson P, Geerards AJM, et al. Influence of topical human epidermal growth factor on postkeratoplasty re-epithelialisation. Br J Ophthalmol. 1997;81:391.","journal-title":"Br J Ophthalmol"},{"key":"4314_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01408-x","volume":"20","author":"HS Moon","year":"2020","unstructured":"Moon HS, Li L, Yoon HJ, Ji YS, Yoon KC. Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea. BMC Ophthalmol. 2020;20:147.","journal-title":"BMC Ophthalmol"},{"key":"4314_CR53","doi-asserted-by":"crossref","unstructured":"Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107:1347-51; discussion 1351-2.","DOI":"10.1016\/S0161-6420(00)00163-9"},{"key":"4314_CR54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.18240\/ijo.2023.01.09","volume":"16","author":"M Hao","year":"2023","unstructured":"Hao M, Cheng Y, Wu J, Wang J. Clinical observation of recombinant human nerve growth factor in the treatment of neurotrophic keratitis. Int J Ophthalmol. 2023;16:60\u20136.","journal-title":"Int J Ophthalmol"},{"key":"4314_CR55","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/ICO.0000000000002974","volume":"41","author":"P Hamrah","year":"2022","unstructured":"Hamrah P, Yavuz Saricay L, Ozmen MC. Cutting edge: topical recombinant nerve growth factor for the treatment of neurotrophic keratopathy-biologicals as a novel therapy for neurotrophic keratopathy. Cornea. 2022;41:673\u20139.","journal-title":"Cornea"},{"key":"4314_CR56","doi-asserted-by":"crossref","unstructured":"Bonzano C, Olivari S, Cutolo CA, Macr\u00ec A, Sindaco D, Borroni D, et al. Recombinant human nerve growth factor (cenegermin)\u2013driven corneal wound healing process: an evidence-based analysis. Front Pharmacol. 2022;12:760507.","DOI":"10.3389\/fphar.2021.760507"},{"key":"4314_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02236-6","volume":"17","author":"A Bruscolini","year":"2022","unstructured":"Bruscolini A, Marenco M, Albanese GM, Lambiase A, Sacchetti M. Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease? Orphanet J Rare Dis. 2022;17:57.","journal-title":"Orphanet J Rare Dis"},{"key":"4314_CR58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s10384-007-0480-z","volume":"51","author":"T Nishida","year":"2007","unstructured":"Nishida T, Chikama T, Morishige N, Yanai R, Yamada N, Saito J. Persistent epithelial defects due to neurotrophic keratopathy treated with a substance P-derived peptide and insulin-like growth factor 1. Jpn J Ophthalmol. 2007;51:442\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"4314_CR59","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/ICO.0000000000001866","volume":"38","author":"J Liu","year":"2019","unstructured":"Liu J, Li L, Li X. Effectiveness of cryopreserved amniotic membrane transplantation in corneal ulceration: a meta-analysis. Cornea. 2019;38:454\u2013462. https:\/\/doi.org\/10.1097\/ICO.0000000000001866.","journal-title":"Cornea"},{"key":"4314_CR60","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archopht.119.5.659","volume":"119","author":"E Letko","year":"2001","unstructured":"Letko E, Stechschulte SU, Kenyon KR, Sadeq N, Romero TR, Samson CM, et al. Amniotic membrane inlay and overlay grafting for corneal epithelial defects and stromal ulcers. Arch Ophthalmol. 2001;119:659\u201363.","journal-title":"Arch Ophthalmol"},{"key":"4314_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/08820538.2012.730105","volume":"28","author":"T Celik","year":"2013","unstructured":"Celik T, Katircioglu YA, Singar E, Kosker M, Budak K, Kasim R, et al. Clinical outcomes of amniot\u0131c membrane transplantat\u0131on in patients with corneal and conjunctival disorders. Semin Ophthalmol. 2013;28:41\u20135.","journal-title":"Semin Ophthalmol"},{"key":"4314_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0002-9394(14)70125-4","volume":"123","author":"SH Lee","year":"1997","unstructured":"Lee SH, Tseng SC. Amniotic membrane transplantation for persistent epithelial defects with ulceration. Am J Ophthalmol. 1997;123:303\u201312.","journal-title":"Am J Ophthalmol"},{"key":"4314_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ajo.2022.12.007","volume":"251","author":"S Sell","year":"2023","unstructured":"Sell S, de la Presa M, Thakur S, Eslani M, Jeffrey J, Sheppard JD, et al. Comparison of persistent epithelial defect treatment with sutureless cryopreserved and dehydrated amniotic membrane. Am J Ophthalmol. 2023;251:32\u201342.","journal-title":"Am J Ophthalmol"},{"key":"4314_CR64","doi-asserted-by":"publisher","unstructured":"Ho KD, Holland L, Elhaddad O, Derek T. Treating corneal epithelial defects using dehydrated human amniotic membrane-derived material: a prospective study. 14 December 2023, PREPRINT (Version 1) available at Research Square [https:\/\/doi.org\/10.21203\/rs.3.rs-3617624\/v1].","DOI":"10.21203\/rs.3.rs-3617624\/v1"},{"key":"4314_CR65","doi-asserted-by":"crossref","unstructured":"Lotfy NM, Al Rashidi S, Hagras SM. Clinical outcomes of vacuum-dehydrated amniotic membrane (Omnigen) mounted on contact lens (Omnilenz) in eyes with acute chemical eye injuries. Graefes Arch Clin Exp Ophthalmol. 2023.","DOI":"10.1007\/s00417-023-06151-9"},{"key":"4314_CR66","unstructured":"Care RCoE. New report exposes real number of A&E waits, as over 1000 patients faced a 12-hour wait in A&E every day in 2021 https:\/\/rcem.ac.uk\/: https:\/\/rcem.ac.uk\/; 2022 [Available from: https:\/\/rcem.ac.uk\/new-report-exposes-real-number-of-ae-waits-as-over-1000-patients-faced-a-12-hour-wait-in-ae-every-day-in-2021\/#:~:text=Notes%20to%20Editor-,There%20is%20a%20total%20of%20124%20NHS%20Trusts%20in%20England]%20Emergency%20Departments%20(A%26Es)."},{"key":"4314_CR67","unstructured":"NHSProviders. The NHS provider sector 2024 [Available from: https:\/\/nhsproviders.org\/topics\/delivery-and-performance\/the-nhs-provider-sector#:~:text=The%20NHS%20provides%20a%20comprehensive,to%20as%20%27secondary%20care%27]."},{"key":"4314_CR68","unstructured":"England N. Local Eye Health Networks - Improving eye health and services NHS England: NHS England; 2023 [NHS England Publications Gateway Reference 00780:[Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2013\/12\/lehn-start-guide.pdf]."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04314-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04314-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04314-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:11:37Z","timestamp":1785517897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04314-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4314"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04314-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This retrospective review was approved as a retrospective audit by the local institutional review boards at Queen Victoria Hospital NHS Trust and Maidstone and Tunbridge Wells NHS Trust and adhered to the Declaration of Helsinki. Informed consent was obtained from all participants, ensuring ethical integrity throughout the study.","order":2,"name":"Ethics","label":"Ethics approval and informed consent","group":{"name":"EthicsHeading","label":"Ethics"}}]}}